Variable | Nilotinib | Dasatinib | Totaln (%) | p-value(2 sided) |
---|---|---|---|---|
Accessibility of the drug in physician institution | ||||
Not at all | 34 (94.44) | 29 (93.55) | 63 (94.03) | 1 |
Very much | 2 (5.56) | 2 (6.45) | 4 (5.97) | |
Cost of drug | ||||
Not at all | 33 (91.67) | 29 (93.55) | 62 (92.54) | 0.081 |
A little | 3 (8.33) | 0 (0) | 3 (4.48) | |
Quite a bit | 0 (0) | 2 (6.45) | 2 (2.99) | |
Patient comorbidity profile | ||||
Not at all | 15 (41.67) | 13 (41.94) | 28 (41.79) | 0.977 |
A little | 6 (16.67) | 4 (12.9) | 10 (14.93) | |
Quite a bit | 13 (36.11) | 13 (41.94) | 26 (38.81) | |
Very much | 2 (5.56) | 1 (3.23) | 3 (4.48) | |
Patient’s age | ||||
Not at all | 18 (50) | 13 (41.94) | 31 (46.27) | 0.797 |
A little | 5 (13.89) | 7 (22.58) | 12 (17.91) | |
Quite a bit | 11 (30.56) | 10 (32.26) | 21 (31.34) | |
Very much | 2 (5.56) | 1 (3.23) | 3 (4.48) | |
Patient’s personality profile | ||||
Not at all | 9 (25) | 11 (35.48) | 20 (29.85) | 0.534 |
A little | 7 (19.44) | 8 (25.81) | 15 (22.39) | |
Quite a bit | 18 (50) | 10 (32.26) | 28 (41.79) | |
Very much | 2 (5.56) | 2 (6.45) | 4 (5.97) | |
Previous discussion about Pros and Cons of both treatments | ||||
Not at all | 5 (13.89) | 3 (9.68) | 8 (11.94) | 0.455 |
A little | 3 (8.33) | 7 (22.58) | 10 (14.93) | |
Quite a bit | 24 (66.67) | 18 (58.06) | 42 (62.69) | |
Very much | 4 (11.11) | 3 (9.68) | 7 (10.45) | |
Different treatment schedules | ||||
Not at all | 21 (58.33) | 13 (41.94) | 34 (50.75) | 0.615 |
A little | 6 (16.67) | 7 (22.58) | 13 (19.4) | |
Quite a bit | 7 (19.44) | 8 (25.81) | 15 (22.39) | |
Very much | 2 (5.56) | 3 (9.68) | 5 (7.46) | |
Type of mutation during IM therapy | ||||
Not at all | 31 (86.11) | 26 (83.87) | 57 (85.07) | 0.460 |
Quite a bit | 4 (11.11) | 2 (6.45) | 6 (8.96) | |
Very much | 1 (2.78) | 3 (9.68) | 4 (5.97) |